Insider Transactions in Q1 2024 at Rayze Bio, Inc. (RYZB)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2024
|
Viking Global Investors LP |
SELL
Other acquisition or disposition
|
Indirect |
13,285,400
-100.0%
|
-
|
|
Feb 26
2024
|
Richard A. Heyman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
367,446
-100.0%
|
$22,781,652
$62.5 P/Share
|
|
Feb 26
2024
|
Maha Katabi |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,419,528
-100.0%
|
$150,010,736
$62.5 P/Share
|
|
Feb 26
2024
|
Susan Moran CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
323,455
-100.0%
|
$20,054,210
$62.5 P/Share
|
|
Feb 26
2024
|
Kenneth Song PRESIDENT AND CHIEF EXECUTIVE |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,622,968
-100.0%
|
$100,624,016
$62.5 P/Share
|
|
Feb 26
2024
|
Arvind Kush CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
78,433
-100.0%
|
$4,862,846
$62.5 P/Share
|
|
Jan 22
2024
|
Susan Moran CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,875
+8.73%
|
$92,625
$3.24 P/Share
|